Log in

CURN Curatis Holding AG SIX · Switzerland

Curatis Holding (CURN) news

Curatis Holding AG is a public biotech or pharmaceutical company listed on SIX under the ticker CURN, recorded under Switzerland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Curatis Holding news

We have not published a story on Curatis Holding yet. When there is news, it will appear here.

Questions about Curatis Holding

What is the ticker symbol of Curatis Holding?

Curatis Holding AG trades under the ticker CURN on SIX.

Where is Curatis Holding listed?

Curatis Holding AG is listed on SIX. Our directory also records these other listings: GETTEX:26U; LS:A40BDL; LSE:0QNS.

Which country or territory is Curatis Holding listed under?

Our directory records Curatis Holding AG under Switzerland.

What does Curatis Holding do?

Our directory classifies Curatis Holding AG as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Curatis Holding?

The ISIN recorded for Curatis Holding AG is CH1330780979.

Does aibio.space cover Curatis Holding?

aibio.space lists Curatis Holding AG among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Curatis Holding?

Companies in our directory listed in the same country and business area as Curatis Holding: Siegfried Holding, Idorsia, Basilea Pharmaceutica, ADC Therapeutics SA, Novartis, MoonLake Immunotherapeutics.

Investor discussion: Curatis Holding

Members talk about Curatis Holding (CURN). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open SIX:CURN on TradingView.

Listing details

Curatis Holding AG is a public biotech or pharmaceutical company listed on SIX under the ticker CURN, recorded under Switzerland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Curatis Holding AG
Ticker
CURN
Listing
SIX
Country or territory
Switzerland
Business scope
Pharmaceuticals: Major
ISIN
CH1330780979
Other listed symbols
GETTEX:26U; LS:A40BDL; LSE:0QNS
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.